Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jacques Simard

Showing results (21-30 of 290) with videos related to

Pageof 29
Sort By:
BMJ Open|March 1, 2018
Disentangling the determinants of interest and willingness-to-pay for breast cancer susceptibility testing in the general population: a cross-sectional Web-based survey among women of Québec (Canada)Jolyane Blouin-Bougie, Nabil Amara, Karine Bouchard, et al.
Breast Cancer Research : BCR|January 19, 2006
BRCA1 and BRCA2 mutation predictions using the BOADICEA and BRCAPRO models and penetrance estimation in high-risk French-Canadian familiesAntonis C Antoniou, Francine Durocher, Paula Smith, et al.
Familial Cancer|November 15, 2011
Self-reported mammography use following BRCA1/2 genetic testing may be overestimatedGeneviève Larouche, Karine Bouchard, Jocelyne Chiquette, et al.
Healthcare Policy = Politiques De Sante|February 21, 2020
Envisioning Implementation of a Personalized Approach in Breast Cancer Screening Programs: Stakeholder PerspectivesDaphne Esquivel-Sada, Emmanuelle Lévesque, Julie Hagan, et al.
Canadian Association of Radiologists Journal = Journal L'Association Canadienne Des Radiologistes|June 20, 2016
Usefulness of Canadian Public Health Insurance Administrative Databases to Assess Breast and Ovarian Cancer Screening Imaging Technologies for BRCA1/2 Mutation CarriersGeneviève Larouche, Jocelyne Chiquette, Marie Plante, et al.
Journal of Pediatric Endocrinology & Metabolism : JPEM|April 23, 2005
17alpha-hydroxylase/17,20-Lyase deficiency due to novel compound heterozygote mutations: treatment for tall stature in a female with male pseudohermaphroditism and spontaneous puberty in her affected sisterKarl Otfried Schwab, Anne-Marie Moisan, Janos Homoki, et al.
Journal of Genetic Counseling|August 16, 2012
Life events may contribute to family communication about cancer risk following BRCA1/2 testingJulie Lapointe, Claudia Côté, Karine Bouchard, et al.
The Journal of Steroid Biochemistry and Molecular Biology|December 16, 2003
Characterization and modulation of sex steroid metabolizing activity in normal human keratinocytes in primary culture and HaCaT cellsSébastien Gingras, Carl Turgeon, Nancy Brochu, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|January 16, 2007
Effect of the Women's Health Initiative study publication on hormone replacement therapy use among women who have undergone BRCA1/2 testingMichel Dorval, Marie-Hélène Vallée, Marie Plante, et al.
Journal of Human Genetics|April 17, 2008
Mutational analysis of the breast cancer susceptibility gene BRIP1 /BACH1/FANCJ in high-risk non-BRCA1/BRCA2 breast cancer familiesFrédéric Guénard, Yvan Labrie, Geneviève Ouellette, et al.
Pageof 29

Showing results (21-30 of 290) with videos related to

Sort By:
Pageof 29
BMJ Open|March 1, 2018
Disentangling the determinants of interest and willingness-to-pay for breast cancer susceptibility testing in the general population: a cross-sectional Web-based survey among women of Québec (Canada)Jolyane Blouin-Bougie, Nabil Amara, Karine Bouchard, et al.
Breast Cancer Research : BCR|January 19, 2006
BRCA1 and BRCA2 mutation predictions using the BOADICEA and BRCAPRO models and penetrance estimation in high-risk French-Canadian familiesAntonis C Antoniou, Francine Durocher, Paula Smith, et al.
Familial Cancer|November 15, 2011
Self-reported mammography use following BRCA1/2 genetic testing may be overestimatedGeneviève Larouche, Karine Bouchard, Jocelyne Chiquette, et al.
Healthcare Policy = Politiques De Sante|February 21, 2020
Envisioning Implementation of a Personalized Approach in Breast Cancer Screening Programs: Stakeholder PerspectivesDaphne Esquivel-Sada, Emmanuelle Lévesque, Julie Hagan, et al.
Canadian Association of Radiologists Journal = Journal L'Association Canadienne Des Radiologistes|June 20, 2016
Usefulness of Canadian Public Health Insurance Administrative Databases to Assess Breast and Ovarian Cancer Screening Imaging Technologies for BRCA1/2 Mutation CarriersGeneviève Larouche, Jocelyne Chiquette, Marie Plante, et al.
Journal of Pediatric Endocrinology & Metabolism : JPEM|April 23, 2005
17alpha-hydroxylase/17,20-Lyase deficiency due to novel compound heterozygote mutations: treatment for tall stature in a female with male pseudohermaphroditism and spontaneous puberty in her affected sisterKarl Otfried Schwab, Anne-Marie Moisan, Janos Homoki, et al.
Journal of Genetic Counseling|August 16, 2012
Life events may contribute to family communication about cancer risk following BRCA1/2 testingJulie Lapointe, Claudia Côté, Karine Bouchard, et al.
The Journal of Steroid Biochemistry and Molecular Biology|December 16, 2003
Characterization and modulation of sex steroid metabolizing activity in normal human keratinocytes in primary culture and HaCaT cellsSébastien Gingras, Carl Turgeon, Nancy Brochu, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|January 16, 2007
Effect of the Women's Health Initiative study publication on hormone replacement therapy use among women who have undergone BRCA1/2 testingMichel Dorval, Marie-Hélène Vallée, Marie Plante, et al.
Journal of Human Genetics|April 17, 2008
Mutational analysis of the breast cancer susceptibility gene BRIP1 /BACH1/FANCJ in high-risk non-BRCA1/BRCA2 breast cancer familiesFrédéric Guénard, Yvan Labrie, Geneviève Ouellette, et al.
Pageof 29